免疫检查点抑制剂相关结肠炎的发病机制

Pathogenesis of Immune Checkpoint Inhibitor-Mediated Colitis

免疫检查点抑制剂(ICI)的临床应用是恶性肿瘤治疗史上飞跃式的进展,它显著改善了患者的生存率,在非小细胞肺癌、胃癌等多种恶性肿瘤中提供了巨大的临床益处。但与此同时,ICI也可通过诱发全身免疫系统的激活而导致免疫相关不良反应(irAE),本文着重对免疫检查点抑制剂相关结肠炎发病机制的研究进展进行综述,以期早期预测、识别发生IMC的高危人群,并据此给予肿瘤患者合理的治疗方案。

The clinical application of immune checkpoint inhibitors (ICI) is a leap forward in the history of ma-lignant tumor treatment. It has significantly improved the survival rate of patients and provided great clinical benefits in various malignant tumors such as non-small cell lung cancer and gastric cancer. However, at the same time, ICI can also induce immune-related adverse events (irAE) by inducing the activation of the systemic immune system. This article focuses on the research pro-gress of the pathogenesis of immune checkpoint inhibitor-mediated colitis, in order to predict and identify the occurrence of high-risk groups of IMC, and accordingly provide reasonable treatment plans for tumor patients.